BCMA-CD19 cCAR T cells / iCell Gene Therap - LARVOL DELTA

BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: iCell Gene Therapeutics

New P1 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

First-in-Human Trial of BCMA-CD19 Compound CAR (cCAR) in Desensitization of Donor-Specific Anti-HLA Antibodies (DSAs) in Haploidentical Stem Cell Transplant Recipients (ASH 2024) - "All patients received conditioning with fludarabine (30 mg/m2/d) and cyclophosphamide (300 mg/m2/d). Remarkable depletion of antibody-producing "roots cause", B cells and plasma/long-lived plasma cells was observed in all patients. Our results suggest cCAR has the potential to benefit patients receiving solid organ transplants or those with other antibody-mediated diseases."

Clinical • P1 data • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Complement-mediated Rare Disorders • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Solid Organ Transplantation • Transplantation

BCMA-CD19 Compound CAR-T (cCAR) Safely Provides a Complete Humoral Reset Eliminating All Autoantibodies Resulting in Long-term Medication-Free Complete Remission Among Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients (ACR Convergence 2024) - "All LN patients at screening treated with HCQ, glucocorticoid, immunosuppressant; majority with belimumab. BCMA-CD19 cCAR can safely achieve long-term medication-free Complete Remission. Will update dataset at ACR. Further research needed."

Clinical • Glomerulonephritis • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Lymphoma • Nephrology • Novel Coronavirus Disease • Oncology • Renal Disease • Systemic Lupus Erythematosus

iCell Presents Positive New Follow-up Clinical Data Confirming BCMA CD19 cCAR Safely Delivers Long-term Medication Free Complete Remission from Systemic Lupus Erythematosus & Lupus Nephritis at EULAR 2024 (Businesswire) - P1 | N=15 | NCT05474885 | Sponsor: iCell Gene Therapeutics | "iCell Gene Therapeutics...today announced new longer-term follow-up data from the Company’s BCMA CD19 compound chimeric antigen receptor (cCAR) T cell immunotherapy development program....'We are excited to progress this therapy in clinical development and plan to file INDs in the United States and China soon.'...Overall, the cCAR therapy was found to be generally safe and well-tolerated. The 10 LN patients receiving the target dose achieved depletion of B cells from peripheral blood within 10 days post-cCAR treatment and depletion of immunoglobulin within 42 days, and complete recovery of B cells and IgM was seen within 2-6 months post-cCAR, IgA within a year and IgG is >400 mg/dL in all patients....The data suggest that cCAR therapy was safe and effective in inducing MFR and depleting disease-causing autoantibodies in SLE and LN patients."

P1 data • Lupus Nephritis • Systemic Lupus Erythematosus

iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus/Lupus Nephritis Published in Annals of the Rheumatic Diseases (Businesswire) - P1 | N=15 | NCT05474885 | Sponsor: iCell Gene Therapeutics | "iCell Gene Therapeutics...today announced the publication in Annals of the Rheumatic Diseases of positive results of an investigator initiated clinical trial (IIT) for its BCMA-CD19 compound chimeric antigen receptor (cCAR) T cell immunotherapy. The clinical trial evaluated the safety and efficacy of a complete humoral reset of both long-lived plasma cells and B cells in 13 systemic lupus erythematosus (SLE) patients treated with iCell’s cCAR, including 11 patients with SLE and lupus nephritis (LN)....iCell considers this IIT to be a successful proof of concept; the Company plans to file an investigational new drug application (IND) for its BCMA-CD19 cCAR in the United States and China....'We look forward to receiving further follow up data confirming the promising results to date, and we plan to present this data on June 12th at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress.'"

P1 data • Systemic Lupus Erythematosus

BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. (PubMed, Ann Rheum Dis) - "Data suggest that cCAR therapy was safe and effective in inducing MFR and depleting disease-causing autoantibodies in patients with SLE."

CAR T-Cell Therapy • Journal • P1 data • Glomerulonephritis • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Lymphoma • Nephrology • Oncology • Systemic Lupus Erythematosus

Immune Reset in B Cell mediated autoimmune diseases using BCMA-CD19 Compound CAR (cCAR) in an open label phase I clinical trial (FOCIS 2023) - No abstract available

Clinical • P1 data • Immunology

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: iCell Gene Therapeutics

CAR T-Cell Therapy • New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • CD19

Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR. (PubMed, Stem Cell Rev Rep) - No abstract available

Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • CD19